Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen

Delcath Systems (NASDAQ:DCTH) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other research firms have also weighed in on DCTH. BTIG Research upped their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research raised shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.17.

Delcath Systems Stock Performance

Shares of DCTH opened at $15.11 on Friday. The firm has a market capitalization of $524.32 million, a P/E ratio of 1,512.51 and a beta of 0.52. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $16.38. The firm has a fifty day moving average price of $12.35 and a 200-day moving average price of $10.88.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million for the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. Analysts predict that Delcath Systems will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its holdings in shares of Delcath Systems by 34.1% in the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after buying an additional 107,391 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Delcath Systems by 58.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock valued at $1,572,000 after acquiring an additional 45,695 shares during the period. JPMorgan Chase & Co. raised its stake in Delcath Systems by 229.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock worth $2,288,000 after acquiring an additional 117,118 shares during the last quarter. Legal & General Group Plc purchased a new position in Delcath Systems in the 2nd quarter worth $46,000. Finally, Rhumbline Advisers acquired a new stake in Delcath Systems during the 2nd quarter worth about $586,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.